Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: A nested case-control study

American Journal of Epidemiology

Volumn 168, Issue 11, 2008, Pages 1284-1291

  Lukanova, Annekatrin ^a,b   Andersson, Ritu ^c   Wulff, Marianne ^c   Zeleniuch Jacquotte, Anne ^a   Grankvist, Kjell ^c   Dossus, Laure ^b   Afanasyeva, Yelena ^a   Johansson, Robert ^c   Arslan, Alan A ^a   Lenner, Per ^c   Wadell, Göran ^c   Hallmans, Göran ^c   Toniolo, Paolo ^a   Lundin, Eva ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Alpha fetoproteins; Breast neoplasms; Chorionic gonadotropin; Pregnancy; Prospective studies

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN;

CANCER; CONCENTRATION (COMPOSITION); HEALTH RISK; HORMONE; IMMUNOASSAY; MATERNAL HEALTH; PREGNANCY;

ADULT; AGE; ARTICLE; BLOOD DONOR; BLOOD SALVAGE; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; PARITY; PREGNANCY; RISK ASSESSMENT;

ADULT; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN; CONFIDENCE INTERVALS; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; ODDS RATIO; PREGNANCY; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; YOUNG ADULT;

EID: 57149120312     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn254     Document Type: Article

References (34)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2(3):133-140.
2. Hinkula M, Pukkala E, Kyyronen P, et al. Grand multiparity and the risk of breast cancer: population-based study in Finland. Cancer Causes Control. 2001;12(6):491-500.
3. Liu Q, Wuu J, Lambe M, et al. Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control. 2002;13(4):299-305.
4. Ewertz M, Duffy SW, Adami HO, et al. Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer. 1990;46(4):597-603.
5. Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia. 1998;3(1):49-61.
6. Medina D. Mammary developmental fate and breast cancer risk. Endocr Relat Cancer. 2005;12(3):483-495.
7. Guzman RC, Yang J, Rajkumar L, et al. Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad Sci U S A. 1999;96(5):2520-2525.
8. Richardson BE, Hulka BS, Peck JL, et al. Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol. 1998;148(8):719-727.
9. Melbye M, Wohlfahrt J, Lei U, et al. Alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence. J Natl Cancer Inst. 2000;92(12):1001-1005.
10. Deutsch HF. Chemistry and biology of alpha-fetoprotein. Adv Cancer Res. 1991;56:253-312.
11. Attardi B, Ruoslahti E. Foetoneonatal oestradiol-binding protein in mouse brain cytosol is alpha foetoprotein. Nature. 1976;263(5579):685-687.
12. Bennett JA, Semeniuk DJ, Jacobson HI, et al. Similarity between natural and recombinant human alpha-fetoprotein as inhibitors of estrogen-dependent breast cancer growth. Breast Cancer Res Treat. 1997;45(2):169-179.
13. Peck JD, Hulka BS, Poole C, et al. Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(4):361-368.
14. Lukanova A, Toniolo P, Zeleniuch-Jacquotte A, et al. Insulin-like growth factor I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2489-2493.
15. Cleveland WS, Loader C. Smoothing by local regression: principles and methods. In: Schimek MG, ed. Statistical Theory and Computational Aspects of Smoothing. New York, NY: Springer Publishing Company; 1996:113-120.
16. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med. 1991;10(11):1665-1677.
17. The endocrinology of pregnancy. In: Speroff L, Fritz M, eds. Clinical Gynecologic Endocrinology and Infertility. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:259-318.
18. Stenman UH, Tiitinen A, Alfthan H, et al. The classification, functions and clinical use of different isoforms of HCG. Hum Reprod Update. 2006;12(6):769-784.
19. Leek AE, Ruoss CF, Kitau MJ, et al. Maternal plasma alpha-fetoprotein levels in the second half of normal pregnancy: relationship to fetal weight, and maternal age and parity. Br J Obstet Gynaecol. 1975;82(8):669-673.
20. Olajide F, Kitau MJ, Chard T. Maternal serum AFP levels in the first trimester of pregnancy. Eur J Obstet Gynecol Reprod Biol. 1989;30(2):123-128.
21. Wald NJ, Watt HC. Serum markers for Down's syndrome in relation to number of previous births and maternal age. Prenat Diagn. 1996;16(8):699-703.
22. Barkai G, Goldman B, Ries L, et al. Effect of gravidity on maternal serum markers for Down's syndrome. Prenat Diagn. 1996;16(4):319-322.
23. Tislaric D, Brajenovic-Milic B, Ristic S, et al. The influence of smoking and parity on serum markers for Down's syndrome screening. Fetal Diagn Ther. 2002;17(1):17-21.
24. Russo J, Russo IH. Biological and molecular bases of mammary carcinogenesis. Lab Invest. 1987;57(2):112-137.
25. Russo J, Balogh GA, Heulings R, et al. Molecular basis of pregnancy-induced breast cancer protection. Eur J Cancer Prev. 2006;15(4):306-342.
26. Russo IH, Koszalka M, Russo J. Human chorionic gonadotropin and rat mammary cancer prevention. J Natl Cancer Inst. 1990;82(15):1286-1289.
27. Russo IH, Russo J. Primary prevention of breast cancer by hormone-induced differentiation. Recent Results Cancer Res. 2007;174:111-130.
28. Sivaraman L, Medina D. Hormone-induced protection against breast cancer. J Mammary Gland Biol Neoplasia. 2002;7(1):77-92.
29. Holl K, Lundin E, Kaasila M, et al. Effect of long-term storage on hormone measurements in samples from pregnant women: the experience of the Finnish Maternity Cohort. Acta Oncol. 2008;47(3):406-412.
30. Garcia-Closas M, Lubin JH. Power and sample size calculations in case-control studies of gene-environment interactions: comments on different approaches. Am J Epidemiol. 1999;149(8):689-692.
31. Crossley JA, Aitken DA, Waugh SM, et al. Maternal smoking: age distribution, levels of alpha-fetoprotein and human chorionic gonadotrophin, and effect on detection of Down syndrome pregnancies in second-trimester screening. Prenat Diagn. 2002;22(3):247-255.
32. Allen NE, Roddam AW, Allen DS, et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer. 2005;92(7):1283-1287.
33. Bernstein L, Lipworth L, Ross RK, et al. Correlation of estrogen levels between successive pregnancies. Am J Epidemiol. 1995;142(6):625-628.
34. Wald NJ, Huttly WJ, Rudnicka AR. Prenatal screening for Down syndrome: the problem of recurrent false-positives. Prenat Diagn. 2004;24(5):389-392.